文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

皮肤利什曼病和内脏利什曼病后皮肤利什曼病(PKDL)的免疫发病机制。

Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL).

机构信息

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Department of Microbiology, College of Arts and Sciences, The Ohio State University, Columbus, OH, United States.

出版信息

Front Cell Infect Microbiol. 2021 Jun 8;11:685296. doi: 10.3389/fcimb.2021.685296. eCollection 2021.


DOI:10.3389/fcimb.2021.685296
PMID:34169006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8217655/
Abstract

Leishmaniasis is a neglected tropical disease that affects 12 million people worldwide. The disease has high morbidity and mortality rates and is prevalent in over 80 countries, leaving more than 300 million people at risk of infection. Of all of the manifestations of this disease, cutaneous leishmaniasis (CL) is the most common form and it presents as ulcerating skin lesions that can self-heal or become chronic, leading to disfiguring scars. This review focuses on the different pathologies and disease manifestations of CL, as well as their varying degrees of severity. In particular, this review will discuss self-healing localized cutaneous leishmaniasis (LCL), leishmaniasis recidivans (LR), mucocutaneous leishmaniasis (MCL), anergic diffuse cutaneous leishmaniasis (ADCL), disseminated leishmaniasis (DL), and Post Kala-azar Dermal Leishmaniasis (PKDL), which is a cutaneous manifestation observed in some visceral leishmaniasis (VL) patients after successful treatment. The different clinical manifestations of CL are determined by a variety of factors including the species of the parasites and the host's immune response. Specifically, the balance between the pro and anti-inflammatory mediators plays a vital role in the clinical presentation and outcome of the disease. Depending upon the immune response, infection can also transition from one form of the disease to another. In this review, different forms of cutaneous infections and their immunology are described.

摘要

利什曼病是一种被忽视的热带病,影响全球 1200 万人。这种疾病的发病率和死亡率都很高,在 80 多个国家流行,超过 3 亿人面临感染风险。在这种疾病的所有表现中,皮肤利什曼病(CL)最为常见,其表现为溃疡性皮肤损伤,可自行愈合或转为慢性,导致毁容性疤痕。本综述重点介绍了 CL 的不同病理学和疾病表现,以及它们的严重程度不同。特别是,本综述将讨论自限性局部皮肤利什曼病(LCL)、复发性利什曼病(LR)、黏膜皮肤利什曼病(MCL)、无反应性弥漫性皮肤利什曼病(ADCL)、播散性利什曼病(DL)和 Kala-azar 后皮肤利什曼病(PKDL),这是一些内脏利什曼病(VL)患者在成功治疗后观察到的皮肤表现。CL 的不同临床表现是由多种因素决定的,包括寄生虫的种类和宿主的免疫反应。具体来说,促炎和抗炎介质之间的平衡在疾病的临床表现和结果中起着至关重要的作用。根据免疫反应,感染也可以从一种疾病形式转变为另一种疾病形式。在本综述中,描述了不同形式的皮肤感染及其免疫学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a1d/8217655/6a5eb689cf6d/fcimb-11-685296-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a1d/8217655/5074fd396216/fcimb-11-685296-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a1d/8217655/6a5eb689cf6d/fcimb-11-685296-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a1d/8217655/5074fd396216/fcimb-11-685296-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a1d/8217655/6a5eb689cf6d/fcimb-11-685296-g002.jpg

相似文献

[1]
Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL).

Front Cell Infect Microbiol. 2021

[2]
PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

PLoS Negl Trop Dis. 2014-11-20

[3]
The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Parasit Vectors. 2016-8-23

[4]
VL-HIV co-infection with Leishmania containing skin lesions resembling para-kala-azar dermal leishmaniasis.

PLoS Negl Trop Dis. 2024-8

[5]
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Trop Med Int Health. 2012-8-12

[6]
Post kala-azar dermal leishmaniasis: A threat to elimination program.

PLoS Negl Trop Dis. 2020-7-2

[7]
Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.

BMC Infect Dis. 2015-11-23

[8]
Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.

Acta Trop. 2021-11

[9]
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.

PLoS Negl Trop Dis. 2017-11-16

[10]
Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.

Br J Dermatol. 2000-7

引用本文的文献

[1]
Spatial Epidemiology of Clinical Forms of Cutaneous Leishmaniasis and Treatment Practice: Evidence from Leishmaniasis Research and Treatment Center, Northwest Ethiopia.

Iran J Parasitol. 2025

[2]
Dysregulated lymphatic remodeling promotes immunopathology during non-healing cutaneous leishmaniasis.

bioRxiv. 2025-5-7

[3]
Guanylate-Binding Proteins Promote Host Defense Against by Balancing iNOS/Arg-1 in Myeloid Cells.

bioRxiv. 2025-6-30

[4]
A novel pan-Leishmania loop-mediated isothermal amplification (Loopamp) assay for diagnosis of cutaneous and visceral leishmaniasis: a systematic review and meta-analysis.

BMC Infect Dis. 2025-5-19

[5]
Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.

Clin Pract. 2025-4-8

[6]
HIF-α signaling regulates the macrophage inflammatory response during infection.

Front Immunol. 2025-3-21

[7]
Leishmaniases: Strategies in treatment development.

Parasite. 2025

[8]
Synthesis and in vitro antitrypanosomatid activity of novel 5-nitroindole-rhodanine conjugates.

Future Med Chem. 2025-3

[9]
Understanding American tegumentary leishmaniasis in urban Montes Claros, Brazil: insights from clinical, immunological and therapeutic investigations.

Parasitology. 2024-9

[10]
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.

Vaccines (Basel). 2024-10-17

本文引用的文献

[1]
Immune Responses in Post Kala-azar Dermal Leishmaniasis.

Indian J Dermatol. 2020

[2]
Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.

Proc Natl Acad Sci U S A. 2020-9-24

[3]
Leishmania Viannia guyanensis, LRV1 virus and extracellular vesicles: a dangerous trio influencing the faith of immune response during muco-cutaneous leishmaniasis.

Curr Opin Immunol. 2020-10

[4]
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.

PLoS Negl Trop Dis. 2020-7-20

[5]
Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14-16 May 2018.

Parasit Vectors. 2020-3-30

[6]
Mucosal and mucocutaneous leishmaniasis in Iran from 1968 to 2018: a narrative review of clinical features, treatments, and outcomes.

Int J Dermatol. 2020-5

[7]
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis.

Int J Parasitol Drugs Drug Resist. 2019-8-22

[8]
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Int J Parasitol Drugs Drug Resist. 2019-6-20

[9]
Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis.

J Dermatolog Treat. 2021-3

[10]
Post-Kala-Azar Dermal Leishmaniasis as a Reservoir for Visceral Leishmaniasis Transmission.

Trends Parasitol. 2019-6-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索